Some old-timers would recognize some of the commen
Post# of 155352
(Total Views: 1087)
Posted On: 08/28/2020 7:28:31 AM
Some old-timers would recognize some of the comments posted below; I have a warm feeling as I wrote this some months before December 2019 when the SP was in free-fall and I was able to purchase shares at discount-value before we took-off.
Is eerily similar these days ….
The importance of getting an approval sometimes is no the approval itself, is the possibility of Off-label use of Leronlimab. And this is just humongous, mainly in Oncology:
We all know that there are many indications (Ohm knows this better than anybody else and has compiled a well-documented list) for which LL likely helps
This is exactly the case for Leronlimab, with one extra, VERY important, benefit added: it is SAFE.
Just imagine what will happen when there is the understanding out here that there is a drug that works for 22 types of cancer (or might work if you will) and does not have any secondary effects. Just imagine !!!!
Many drugs are being used right now with substantial SAEs and still are being prescribed of-label by physicians!!!
One of the perceived drawbacks is the fact that OFF-label drugs are not covered by insurance. This is not the case to a large extent nowadays:
My point being: once we get an approval the dam will come down and zillions of “water” will pour downstream, if you follow my symbolism:
I hope we will be in high ground when this happens … and is the reason I have been purchasing stock as of late in spite of being waaaaay overweight already.
So, how big is this market ?. Whatever you want to call it. I remember the famous quote from Garcia Marquez’s book “The Autumn of the Patriarch” when the dictator, in one of his sleepless nights when he used to ambulate by the empty corridors of his large palace asks a guard soldier: “soldier, what time is it??” And the soldier going to attention answers, “whatever time you want it to be, sir”
Therefore, how large is really the potential market ?? Let me indulge throwing a simple google search (“what is the oncology market size”) here:
Just apply the percentage you like. Of course, I am disregarding other huge indications: NASH, HIV, +, + …
Let me repeat: is eerly similar to December 2019 …
Maybe I had my coffee too charged this morning
Is eerily similar these days ….
The importance of getting an approval sometimes is no the approval itself, is the possibility of Off-label use of Leronlimab. And this is just humongous, mainly in Oncology:
Quote:
• Some cancer drugs are found to work against many different kinds of tumors.
• Chemotherapy treatments often combine drugs. These combinations might include one or more drugs not approved for that disease. Also, drug combinations change over time as doctors study different ones to find out which work best.
• Cancer treatment is always changing and improving.
• Oncologists (cancer doctors) and their patients are often faced with problems that have few approved treatment options. This is especially true for less common types of cancer.
• Oncologists and their patients may be more willing to try off-label drugs than other medical specialties.
We all know that there are many indications (Ohm knows this better than anybody else and has compiled a well-documented list) for which LL likely helps
This is exactly the case for Leronlimab, with one extra, VERY important, benefit added: it is SAFE.
Just imagine what will happen when there is the understanding out here that there is a drug that works for 22 types of cancer (or might work if you will) and does not have any secondary effects. Just imagine !!!!
Many drugs are being used right now with substantial SAEs and still are being prescribed of-label by physicians!!!
Quote:
A 2008 study found that 8 out of 10 cancer doctors surveyed had prescribed drugs off-label. Off-label drug use is also well-documented and very common in certain other settings, such as in pediatrics and HIV/AIDS care.
Studies have reported that about half of the chemotherapy drugs used are given for conditions not listed on the FDA-approved drug label. In fact, the National Cancer Institute (NCI) has stated, “Frequently the standard of care for a particular type or stage of cancer involves the off-label use of one or more drugs.
One of the perceived drawbacks is the fact that OFF-label drugs are not covered by insurance. This is not the case to a large extent nowadays:
Quote:
The biggest problem is getting insurance plans to pay (reimburse) for off-label drug use. Many insurance companies will not pay for an expensive drug that’s used in a way that’s not listed in the approved drug label. They do this on the grounds that its use is “experimental” or “investigational.”
In cancer treatment, these issues have been largely addressed through 1993 federal legislation that requires insurance to cover medically appropriate cancer therapies. This law includes off-label uses if the treatment has been tested in careful research studies and written up in well-respected drug reference books or medical journals. In 2008, Medicare rules were changed to cover more off-label uses of cancer treatment drugs.
My point being: once we get an approval the dam will come down and zillions of “water” will pour downstream, if you follow my symbolism:
Quote:
A systematic literature search was performed in PubMed as per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines from 1975 to 2016. Studies assessing the prevalence of off-label use of anticancer drugs were included. Data synthesis: Of the 199 eligible papers retrieved, 23 studies were included in this systematic literature review. Off-label drug use in inpatients ranged from 18% to 41%. Among adult patients with cancer, 13%-71% received a minimum of one off-label chemotherapy. The main reasons for off-label drug use were 'drug unapproved for specific tumour' and 'modified drug applications'. Among adults, metastatic cancers and palliative care patients received the most off-label drugs. The off-label drug use unsupported by standard treatment guidelines or drug compendia was in the range of 7%-31%.
I hope we will be in high ground when this happens … and is the reason I have been purchasing stock as of late in spite of being waaaaay overweight already.
So, how big is this market ?. Whatever you want to call it. I remember the famous quote from Garcia Marquez’s book “The Autumn of the Patriarch” when the dictator, in one of his sleepless nights when he used to ambulate by the empty corridors of his large palace asks a guard soldier: “soldier, what time is it??” And the soldier going to attention answers, “whatever time you want it to be, sir”
Therefore, how large is really the potential market ?? Let me indulge throwing a simple google search (“what is the oncology market size”) here:
Quote:
The global oncology/cancer drugs market was valued at $97,401 million in 2017, and is estimated to reach at $176,509 million by 2025, registering a CAGR of 7.6% from 2018 to 2025.
Just apply the percentage you like. Of course, I am disregarding other huge indications: NASH, HIV, +, + …
Let me repeat: is eerly similar to December 2019 …
Maybe I had my coffee too charged this morning
(16)
(0)